Rhythm Pharma (RYTM) Q3 2026 Earnings Call Transcript

Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, up 29% sequentially, with U.S. acquired hypothalamic obesity launch demand driving most of the growth; reimbursed patients increased 20% quarter over quarter. The company ended September with $320.9 million in cash and short-term investments, which management expects to fund operations for at least 24 months, and secured a term-loan facility of up to $750 million, initially drawing $250 million at SOFR plus 4.6%. Rhythm also agreed to pay LG Chem $350 million over four years to reduce MC4R portfolio royalties to 1%, and set 2026 non-GAAP operating expense guidance at $360 million-$380 million; Japan launched in October, while Phase III trials for bivamelagon are planned in acquired HO and Prader-Willi syndrome.

Analysis

The key underwriting question is whether start-form growth converts into durable, reimbursed treatment—not whether early launch revenue can keep compounding at the reported sequential rate. Diagnosis and physician education are the real bottlenecks: coverage appears less constraining than the time required to identify patients, confirm acquired HO, and move them through busy specialist practices. That makes patient conversion, repeat prescribing, and persistence more informative than raw start forms over the next 1–3 quarters. Also separate underlying demand from shipment timing and the prior French charge; reported revenue is not yet a clean read-through to patient consumption.

Japan is a longer-dated option, not a near-term offset to U.S. execution risk. The two-week dispensing cadence until November 2027 creates recurring hospital friction and could make the identified-patient pool convert slowly; the later supply extension is a plausible acceleration catalyst, not guaranteed uptake. Europe adds another staggered reimbursement path.

The royalty buy-down improves future economics if the portfolio scales, but the financing shifts risk forward: scheduled LG payments plus floating-rate debt make the next several years more capital-intensive than the quarter-end cash balance alone suggests. Verify pro forma liquidity after the initial payment and borrowing, debt covenants, and interest sensitivity. Bivamelagon’s pivotal programs add meaningful upside, but PWS remains binary and scientifically difficult; avoid treating management’s confidence as de-risking.

Contrarian read: launch momentum may be over-extrapolated from early revenue, while the market may underweight the length of the diagnosis funnel and Japan’s access friction. Conversely, if reimbursed-patient growth and repeat prescribing hold while pharmacy inventory normalizes, consensus may be underestimating the duration of the U.S. opportunity.

Key Decisions for Investors

• RYTM: Do not chase a launch-driven gap higher. Prefer staged exposure on weakness, adding only if the next 1–2 quarters show continued growth in reimbursed patients and repeat prescribers, with channel inventory not doing the work. Falsify the thesis if paid-patient growth stalls or management signals weaker persistence.
• Track start-form-to-paid conversion, time to approval, patient discontinuations, repeat prescriptions, and specialty-pharmacy days on hand. Treat start-form totals and shipment revenue as leading/volatile indicators, not a substitute for treated-patient evidence.
• Model pro forma cash after the initial LG payment and the first term-loan draw; stress SOFR and scheduled payments through 2029. Reassess if runway falls materially below management’s stated horizon or if debt terms constrain development/commercial spending.
• Keep bivamelagon and Japan as catalyst optionality rather than base-case value: monitor HO Phase III enrollment/timing, regulatory alignment and PWS trial design; in Japan, watch conversion from identified candidates to treated patients and reassess after the two-week dispensing restriction is expected to lift in November 2027.